Your Global Leader in Stem Cell Market Research
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, announced the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538.
FT538 is the first CRISPR-edited, iPSC-derived cell therapy under development worldwide. [Read more…]
Author: Jean-Philippe Richard, Ph. D. ([email protected])
Parkinson’s Disease (PD) affects some 10 million people worldwide, most commonly in patients over the age of 50. PD is associated with the loss of dopaminergic neurons in the substantia nigra region of the brain, leading to the characteristic tremors in the extremities, among other symptoms. There is a need for models of PD to help discover new therapies. To help address this need, we generated and characterized iPSC-derived PD dopaminergic neurons as a test case for functional neural differentiation. [Read more…]
CellPlan is a revolutionary stem cell insurance product launched by WideCells Group in Manchester, UK. WideCells Group aims to provide people with access to affordable stem cell treatments. In this interview, CEO  Joao Andrade describes how the company will facilitate the therapeutic use of umbilical cord blood stem cells by providing worldwide access to stem cell specialists and hospitals.
In this article:
PALO ALTO, Calif., May 15, 2020 — I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-wining technology “induced pluripotent stem cell (iPSC)” began manufacturing clinical-grade iPSCs. We are now officially taking orders for custom manufacturing of clinical-grade iPSCs from institutions around the world.
On March 11, 2020, the company received a license to manufacture clinical-grade cells from Japan’s Ministry of Health, Labour and Welfare for its cell manufacturing facility located in Kyoto, Japan. [Read more…]
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types.
There are now hundreds of companies developing stem cell research products — many of which are serving companies involved in the management of the largest pandemic in modern history. [Read more…]
